Rob Dillard

DocwireNews

This week, the US Food and Drug Administration (FDA) <a href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-chemotherapy-primary-advanced-or-recurrent-endometrial-carcinoma" target="_blank" rel="noopener">approved</a> pembrolizumab with carboplatin and paclitaxel for adult patients with primary advanced or recurrent endometrial carcinoma.The efficacy of this treatment combination was assessed in KEYNOTE-868/NRG-GY018, a multicenter, randomized, double-blind, placebo-controlled trial comprising 810 patients with advanced or recurrent endometrial carcinoma. The trial, consisting of 2 separate cohorts based on mismatch repair (MMR) status, included 222 patients in the MMR deficient (dMMR) cohort and 588 patients in the MMR proficient (pMMR) cohort. Subsequently, study subjects were randomized (1:1) to the following treatment arms:<ul>
<li>Pembrolizumab 200 mg every 3 weeks, paclitaxel 175 mg/m2 and carboplatin AUC 5 mg/mL/min for 6 cycles, followed by pembrolizumab 400 mg every 6 weeks for up to 14 cycles</li>
<li>Placebo every 3 weeks, paclitaxel 175 mg/m2 and carboplatin AUC 5 mg/mL/min for 6 cycles, followed by placebo every 6 weeks for up to 14 cycles</li>
</ul>The key efficacy end point was defined as progression-free survival (PFS).According to the results, in the dMMR cohort, median PFS was not reached (NR; 95% CI, 30.7 to NR) in the pembrolizumab and chemotherapy arm and 6.5 months (95% CI, 6.4-8.7) in the placebo and chemotherapy arm (hazard ratio [HR], 0.30 [95% CI: 0.19-0.48]; P-value&lt;.0001). However, in the pMMR cohort, median PFS was 11.1 months (95% CI, 8.7-13.5) in the pembrolizumab and chemotherapy arm and 8.5 months (95% CI, 7.2-8.8) in the placebo and chemotherapy arm (HR, 0.60 [95% CI: 0.46-0.78; P-value&lt;.0001).

Eric Bergson, MD

The Role of Multidisciplinary Care in Head and Neck Cancer

Head and Neck Cancer

Sara Nunnery, MD, MSCI

Trastuzumab Deruxtecan in HER2-Low Breast Cancer: Who’s the Right Patient?

HER2 Breast Cancer

Meghan Sise, MD

Joel M. Topf, MD, FACP

Redefining Carboplatin Dosing

NKF Spring Clinical Meetings 2025

Latest News

FDA Approves Pembrolizumab With Chemotherapy for Advanced, Recurrent Endometrial Cancer

Gynecologic Cancer

The FDA approved pembrolizumab with chemotherapy for adult patients with primary advanced or recurrent endometrial carcinoma. 

FDA Approves Pembrolizumab With Chemotherapy for Advanced or Recurrent Endometrial Cancer

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe